Warning letters, 483s, Recalls, Import Alerts, Audit observations
The USFDA Warning letter to K. C. Pharmaceuticals issued in August 2023, following inspection at
Biocon Malaysia was inspected by USFDA Investigators Eileen A. Liu, Patty P. Kaewussdangkul, Daniel Lahar,
USFDA 483 to Intas cites lapses in investigation and review of failures and discrepancies in
Catalent USFDA 483 /Bloomington (FEI :3005949964)/ Inspection Dates: May 4-12, 2023 / Inspectors: Wayne Scifert,
FDA published the USFDA483 issued to Intas site (FEI 3003157498) in Ahmedabad, India after inspection
